AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions. We are using an innovative, multi-modal approach that recognizes neuro-inflammation as a root cause of neuro-degeneration, leveraging the ability of cromolyn, a small molecule with a well-characterized safety profile, to shift the brain’s innate immune cells from a pro-inflammatory to neuroprotective state. We are advancing a pipeline of candidates in Alzheimer's Disease, amyotrophic lateral sclerosis (ALS) and post-ischemic stroke cognitive impairment.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $53.6M
Founded date: 2011
Investors 3
| Date | Name | Website |
| - | Dolby Fami... | dolbyventu... |
| - | Cavendish ... | cavendishf... |
| 11.08.2022 | Black Gran... | blackgrani... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.10.2020 | Series C | $33.6M | - |
| 07.12.2015 | - | $20M | - |
Mentions in press and media 7
| Date | Title | Description |
| 02.10.2020 | AZTherapies Closes $33.6M Series C-1 Financing | AZTherapies, Inc., a Boston, MA-based biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, closed a $33.6m Series C-1 financing. This C-1 round follows the receipt earlier this year of an additional $11... |
| 30.09.2020 | AZTherapies Closes $33.6 Million Series C-1 | BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the closing of a $33.6 million Series C-1 Preferred Stock financing. ... |
| 29.09.2020 | AZTherapies Announces Closing of $33.6 Million Series C-1 Financing Building Upon Recent $37.5 Million Series C Financing | BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the closing of a $33.6 million Series C-1 Preferred Stock financing. ... |
| 17.10.2019 | After 13% discount Innate Pharma raises $69M; AZTherapies bags $26.3M from Series C financing round | → AstraZeneca-partnered French biotech Innate Pharma — which was shooting for a $100 million IPO by offering 10.7 millions shares at $7.50 per share last month — has raised $69 million in the US by offering 12.5 million shares ... |
| 17.10.2019 | AZTherapies Closes $26.3M Series C | BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the closing of a $26.3 million Series C Preferred equity financing. This round was co-l... |
| 07.12.2015 | AZTherapies raising $20M, in Phase 3 trials for reformulated drugs that treat Alzheimer’s disease | “Confronting two triggering causes associated with Alzheimer’s disease progression simultaneously provides a new multifunctional treatment approach for modifying disease progression,” said Dr. David Elmaleh, the company’s founder and direct... |
| - | AZTherapies raising $20M, in Phase 3 trials for reformulated drugs that treat Alzheimer’s disease | AZTherapies, a Massachusetts General Hospital spinout testing combinations of reformulated drugs to treat Alzheimer’s, is in the midst of a $20 million financing round, according to an SEC filing. The company is developing a small molecule ... |